Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. EPRX
stocks logo

EPRX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.136
-41.78%
--
--
-0.163
-22.22%
--
--
-0.167
-35.9%
Estimates Revision
The market is revising No Change the revenue expectations for Eupraxia Pharmaceuticals Inc. (EPRX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 8.91%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+8.91%
In Past 3 Month
Wall Street analysts forecast EPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EPRX is 10.39 USD with a low forecast of 6.41 USD and a high forecast of 12.05 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast EPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EPRX is 10.39 USD with a low forecast of 6.41 USD and a high forecast of 12.05 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.870
sliders
Low
6.41
Averages
10.39
High
12.05
Current: 5.870
sliders
Low
6.41
Averages
10.39
High
12.05
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$12
2025-08-20
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$12
2025-08-20
maintain
Buy
Reason
H.C. Wainwright believes Celldex's (CLDX) Phase 2 data for barzolvolimab in patients with eosinophilic esophagitis supports the positive thesis on Eupraxia Pharmaceuticals (EPRX). Barzolvolimab did not show improvements in eosinophilic esophagitis symptoms or endoscopic measures of disease activity compared to placebo, the analyst tells investors in a research note. The firm says a potential competitor to Eupraxia in eosinophilic esophagitis has been removed. The barzolvolimab study also validates the "simpler but more effective approach" Eupraxia is taking with EP-104GI, contends H.C. Wainwright. The firm has a Buy rating on the shares with a $12 price target.
Cantor Fitzgerald
NULL -> Overweight
initiated
$11
2025-07-24
Reason
Cantor Fitzgerald
Price Target
$11
2025-07-24
initiated
NULL -> Overweight
Reason
Cantor Fitzgerald initiated coverage of Eupraxia Pharmaceuticals with an Overweight rating and $11 price target.
H.C. Wainwright
NULL -> Buy
initiated
$12
2025-06-26
Reason
H.C. Wainwright
Price Target
$12
2025-06-26
initiated
NULL -> Buy
Reason
Canaccord
Speculative Buy
initiated
$9
2025-06-17
Reason
Canaccord
Price Target
$9
2025-06-17
initiated
Speculative Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Eupraxia Pharmaceuticals Inc (EPRX.O) is -9.18, compared to its 5-year average forward P/E of -3.66. For a more detailed relative valuation and DCF analysis to assess Eupraxia Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.66
Current PE
-9.18
Overvalued PE
-0.80
Undervalued PE
-6.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.93
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.16
Undervalued EV/EBITDA
-5.69

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

EPRX News & Events

Events Timeline

(ET)
2025-11-13
17:11:02
Eupraxia Pharmaceuticals' EP-104GI Demonstrates Effectiveness in Latest Esophagitis Results
select
2025-09-29 (ET)
2025-09-29
17:01:26
Eupraxia reveals 'promising' results from top-dose group in RESOLVE trial
select
2025-09-23 (ET)
2025-09-23
06:15:25
Eupraxia Pharmaceuticals Sets Price at $5.50 for 12.727 Million Share Spot Secondary Offering
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-14Newsfilter
Eupraxia Pharmaceuticals Shares New 52-Week Follow-Up Data from the RESOLVE Trial on Eosinophilic Esophagitis (EoE) Showing Consistent Outcomes with EP-104GI Treatment

  • Clinical Trial Results: Cohorts 5 and 6 of the RESOLVE trial show that 4 out of 6 patients remain in clinical remission 52 weeks after a single administration of EP-104GI for eosinophilic esophagitis (EoE), with no serious adverse events reported.

  • Durability and Tolerability: The data indicates a durable clinical symptom response, with 67% of patients in clinical remission at week 36 and significant reductions in dysphagia symptoms measured by the Straumann Dysphagia Index.

  • Innovative Treatment Approach: EP-104GI, administered via esophageal wall injections, represents a novel treatment strategy for EoE, potentially offering a once-a-year treatment option that aligns with routine patient endoscopies.

  • Future Developments: Eupraxia Pharmaceuticals plans to disclose additional data from the RESOLVE trial and is currently recruiting for the Phase 2b part of the trial, with top-line data expected in Q3 2026.

[object Object]
Preview
1.0
09-25Newsfilter
Peterson Capital Organizes Canada Growth Conference in Ireland

  • Canada Growth Conference: The third Canada Growth Conference is taking place in Dublin, hosted by Peterson Capital, featuring seven of Canada's fastest-growing public companies and over fifty industry professionals.

  • Event Highlights: Attendees will engage in presentations, networking, and a unique 'Bear Pit' session with CEOs, culminating in a vote for the top growth story, with the winner receiving the Canada Growth Cup.

[object Object]
Preview
8.5
09-24Newsfilter
Eupraxia Pharmaceuticals Completes $80.5 Million Public Offering with Full Underwriter Option Exercised

  • Successful Public Offering: Eupraxia Pharmaceuticals closed a public offering of 14,636,363 common shares at $5.50 each, raising approximately $80.5 million to support the development of its drug EP-104GI and other clinical initiatives.

  • Use of Proceeds: The funds will primarily be used for advancing the product pipeline, including clinical trials, regulatory submissions, and expanding the company's intellectual property portfolio, with a focus on addressing significant unmet medical needs.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Eupraxia Pharmaceuticals Inc (EPRX) stock price today?

The current price of EPRX is 5.87 USD — it has decreased -1.43 % in the last trading day.

arrow icon

What is Eupraxia Pharmaceuticals Inc (EPRX)'s business?

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.

arrow icon

What is the price predicton of EPRX Stock?

Wall Street analysts forecast EPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EPRX is 10.39 USD with a low forecast of 6.41 USD and a high forecast of 12.05 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Eupraxia Pharmaceuticals Inc (EPRX)'s revenue for the last quarter?

Eupraxia Pharmaceuticals Inc revenue for the last quarter amounts to -6.52M USD, increased 12.42 % YoY.

arrow icon

What is Eupraxia Pharmaceuticals Inc (EPRX)'s earnings per share (EPS) for the last quarter?

Eupraxia Pharmaceuticals Inc. EPS for the last quarter amounts to -4566933.00 USD, decreased -55.37 % YoY.

arrow icon

What changes have occurred in the market's expectations for Eupraxia Pharmaceuticals Inc (EPRX)'s fundamentals?

The market is revising No Change the revenue expectations for Eupraxia Pharmaceuticals Inc. (EPRX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 8.91%.
arrow icon

How many employees does Eupraxia Pharmaceuticals Inc (EPRX). have?

Eupraxia Pharmaceuticals Inc (EPRX) has 33 emplpoyees as of December 05 2025.

arrow icon

What is Eupraxia Pharmaceuticals Inc (EPRX) market cap?

Today EPRX has the market capitalization of 297.31M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free